<?xml version="1.0" encoding="UTF-8"?>
<p>Our study seems to confirm previously published data showing that there are significant differences in the immune response between EVD fatal and survivor patients, both in antibodies and inflammatory mediators, which likely contribute to the outcome of the disease. O
 <styled-content style="color:#222222">ur study suggests an important dysregulation of several cytokines in the fatal group as compared to the survivors in the late phase of infection showing high levels of pro-inflammatory mediators, which play a role in the immune system. This </styled-content>sustained and excessive alteration 
 <styled-content style="color:#222222">in the fatal group may be related to the failure to produce anti-EBOV immunoglobulins and finally, to the inability to control virus replication and disease progression in fatal outcomes.</styled-content>
</p>
